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Abstract
EGFRmutation-induced drug resistance has become a major threat to the treatment of
non-small-cell lung carcinoma. Essentially, the resistance mechanism involves modifica-
tions of the intracellular signaling pathways. In our work, we separately investigated the
EGFR and ErbB-3 heterodimerization, regarded as the origin of intracellular signaling path-
ways. On one hand, we combined the molecular interaction in EGFR heterodimerization
with that between the EGFR tyrosine kinase and its inhibitor. For 168 clinical subjects, we
characterized their corresponding EGFRmutations using molecular interactions, with three
potential dimerization partners (ErbB-2, IGF-1R and c-Met) of EGFR and two of its small
molecule inhibitors (gefitinib and erlotinib). Based on molecular dynamics simulations and
structural analysis, we modeled these mutant-partner or mutant-inhibitor interactions using
binding free energy and its components. As a consequence, the mutant-partner interactions
are amplified for mutants L858R and L858R_T790M, compared to the wild type EGFR. Mu-
tant delL747_P753insS represents the largest difference between the mutant-IGF-1R inter-
action and the mutant-inhibitor interaction, which explains the shorter progression-free
survival of an inhibitor to this mutant type. Besides, feature sets including different energy
components were constructed, and efficient regression trees were applied to map these
features to the progression-free survival of an inhibitor. On the other hand, we comparably
examined the interactions between ErbB-3 and its partners (EGFRmutants, IGF-1R, ErbB-
2 and c-Met). Compared to others, c-Met shows a remarkably-strong binding with ErbB-3,
implying its significant role in regulating ErbB-3 signaling. Moreover, EGFR mutants corre-
sponding to poor clinical outcomes, such as L858R_T790M, possess lower binding affini-
ties with ErbB-3 than c-Met does. This may promote the communication between ErbB-3
and c-Met in these cancer cells. The analysis verified the important contribution of IGF-1R
or c-Met in the drug resistance mechanism developed in lung cancer treatments, which may
bring many benefits to specialized therapy design and innovative drug discovery.
PLOS ONE | DOI:10.1371/journal.pone.0128360 May 20, 2015 1 / 27
a11111
OPEN ACCESS
Citation:Wang DD, Ma L, Wong MP, Lee VHF, Yan
H (2015) Contribution of EGFR and ErbB-3
Heterodimerization to the EGFR Mutation-Induced
Gefitinib- and Erlotinib-Resistance in Non-Small-Cell
Lung Carcinoma Treatments. PLoS ONE 10(5):
e0128360. doi:10.1371/journal.pone.0128360
Academic Editor: Huei-Wen Chen, Graduate
Institute of Toxicology, TAIWAN
Received: October 31, 2014
Accepted: April 25, 2015
Published: May 20, 2015
Copyright: © 2015 Wang et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work is supported by the Hong Kong
Health and Medical Research Fund (Project
01121986) and City University of Hong Kong (Project
9610308). The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
The human epidermal growth factor receptor (EGFR), belonging to the ErbB family of receptor
tyrosine kinases (RTK), plays a significant role in the pathogenesis and progression of different
carcinoma types, and thus it has become a major topic in cancer research [1–3]. An EGFR-fam-
ily receptor is composed of an extracellular ligand-binding domain, a hydrophobic transmem-
brane domain, and an intracellular tyrosine kinase domain [1–4]. A number of ligands, such as
EGF, transforming growth factor-α (TGF-α) and neuregulins (NRGs) [5, 6], can activate
EGFR-family receptors, directly provoking them to homo- or heterodimerize [5, 7]. The critical
role of dimerization among the EGFR family, in receptor activation and signaling diversity, has
long been elucidated [6, 8–10]. Upon dimerization, the catalytic activity of the intracellular ty-
rosine kinase domain is stimulated, promoting the autophosphorylation of specific tyrosine
residues [6, 11]. These phosphorylated residues provide docking sites for downstream signaling
molecules (such as Shc, Grb2 and PI3K) containing Src homology 2 (SH2) or phosphotyrosine
binding (PTB) domains, the recruitment of which switches on intracellular signals [5, 7]. In
EGFR-downstream signaling cascades, Ras/Raf/Mek/Erk and PI3K/Akt/mTOR are two general
pathways [7]. Ultimately, signals will be converted to specific proliferative/apoptotic responses
once they arrive the cell nucleus. A profile of this mechanism is displayed in Fig 1a.
Abnormally-amplified signaling can result in malignant cell proliferation (carcinoma) [4,
12]. As the EGFR signaling pathway is well-acknowledged as a leading pathway during the de-
velopment of many carcinoma types [7, 12, 13], EGFR has become a rational and important
therapeutic target [7, 14]. One group of agents that target the kinase domain of EGFR, called
tyrosine kinase inhibitors (TKIs), are clinically active and broadly applied in the treatments of
cancers such as non-small-cell lung carcinoma (NSCLC) [4, 13, 15]. Such agents bind to the
ATP-binding cave of EGFR kinases, leading to the blockade of kinase catalytic activity and to
the attenuated signaling pathways. Specifically in NSCLC treatments, two reversible TKIs, gefi-
tinib (IRESSA) and erlotinib (TARCEVA), are used primarily [16–18]. The rough binding sites
(on wild-type EGFR) for gefitinib and erlotinib can be referred to in Fig 1b. More importantly,
these TKIs are especially effective in NSCLC patients that harbor activating mutations in their
EGFR kinases (Fig 1c) [13, 16]. As reported, mutations clustered around the ATP-binding
pocket of EGFR kinase domain frequently occur in NSCLC [15, 16], and different mutation
types normally correspond to diverse clinical responses to TKIs [17]. A well-known mutation
at the kinase activation loop, the substitution of leucine with arginine at residue site 858
(L858R), showed a good response to these TKIs [4, 15, 19]. However, the efficacy can only last
for a short period of time, before drug resistance occurs, probably due to a second mutation
such as L858R_T790M at site 790 [15, 20]. One possible reason for this EGFR mutation-driven
resistance is the steric interference caused by the mutation [15, 21], which results in a decreased
binding affinity between the EGFR mutant and an inhibitor [22]. In fact, it has been verified ex-
perimentally that, mutant L858R has a higher binding affinity with Gefitinib or Erlotinib than
mutant L858R_T790M [19, 22, 23].
Another major focus in the study of EGFR mutation-induced drug resistance is EGFR di-
merization [5–8]. EGFR signaling pathways originate form EGFR dimerization, which pro-
duces signaling diversity and is closely associated with cancer development and malignancy [4,
9, 24, 25]. More specially, EGFR heterodimers might have reduced receptor internalization and
degradation as compared with homodimers, which thereby can result in enhanced signaling
[14]. In this regard, EGFR heterodimers should be a valuable target to be investigated [4, 5].
For the kinase domains of EGFR and its partners, the dimerization mechanism is an allosteric
one [20] that highly resembles the one in a CDK/cyclin-like complex [26, 27]. This kinase do-
main consists of an N-terminal lobe (N-lobe) face, composed mostly of β-strands and one α-
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helix, and a C-terminal lobe (C-lobe) face, largely made of α-helices. Normally in a dimer, the
C-lobe face of one receptor kinase is closer to the N-lobe face coupled with the ATP-binding
pocket of the other receptor kinase, encouraging the cross-phosphorylation of the two partners
(Fig 1d) [4, 11, 20, 28]. The formation of this asymmetric kinase-dimer has been demonstrated
to be an essential prerequisite of receptor activation in the EGFR family [4, 20, 25, 29]. To fur-
ther investigate the requirements of this activation, Zhang et al. [20] implemented a variety of
transfection/cotransfection experiments based a number of EGFR mutants, involving
Fig 1. EGFR downstream signaling and EGFR dimerization. (a) A profile of the activation and transduction of EGFR downstream signals. (b) Binding-site
residues (of WT EGFR) for two TKIs (Gefitinib and Erlotinib). (c) A sketch of the binding between an EGFR kinase mutant and a TKI, with primary binding-site
residues listed. (d) The allosteric mechanism for kinase dimerization of EGFR and its partner. (e) The kinase dimerization for a TKI-blocked EGFR and its
potential partner. (f) The average expressions of ErbB receptors in breast carcinoma, NSCLC and Colon carcinoma. (g) The proliferation of H460/TKI-R cells
when treated with AG1024 or continuous Erlotinib. (h) The effects of depletion of c-Met, EGFR, ErbB-2 and ErbB-3 on cell proliferation of EBC-1 and H1993
cell lines.
doi:10.1371/journal.pone.0128360.g001
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mutations in the ATP-binding site (kinase-dead), N-lobe face and C-lobe face of the dimer in-
terface. Interestingly, according to their outcomes, a kinase-dead receptor with an intact C-
lobe face could successfully interact with a partner having an intact N-lobe face and an effective
ATP-binding site after ligand stimulation. This study may shed light on our investigation of
EGFR mutation-induced drug resistance. Considering the TKI-blocked EGFR kinases as dead
ones, they are still able to provide the C-lobe face in the interaction with their dimerization
partners as shown in Fig 1e [4, 20], and these interactions are most probably amplified.
Manifestly, other receptors in the EGFR (ErbB) family, namely ErbB-2, ErbB-3 and ErbB-4,
are first candidates for EGFR heterodimerization. The EGFR-family members share a high de-
gree of homology in their tyrosine kinase domains, making them favorable dimerization part-
ners [5, 7, 14]. Evidence suggests that cooperation in the ErbB receptor/ligand network can
produce signaling diversity and is necessary to induce cell transformation or cancer progres-
sion [7, 12]. In Fig 1f, the average expressions of ErbB receptors, reviewed from a series of pub-
lications [7, 14, 30–32], are displayed. As shown in this figure, EGFR and ErbB-3 are primarily
expressed in human carcinomas (50%* 70%); ErbB-2 is expressed in 20%* 30% of these
carcinomas; and the expression of ErbB-4 occurs only in breast and colon carcinomas. In this
regard, ErbB-2 and ErbB-3 are considered in our study. ErbB-2 has a powerful tyrosine kinase
activity and its extracellular domain is always in an ‘active’ format [2, 33], promoting it to be
an ideal partner for all other ErbB receptors [5, 14]. Reciprocally, ErbB-3 is kinase-impaired [6,
14], and thus it is not a preferred partner for a TKI-blocked EGFR. However, it can still be acti-
vated by other potential partners such as ErbB-2 [5, 6, 8, 14]. These will be discussed detailedly
in the Results and Discussion sections.
Recently, both in vitro and in vivo studies have demonstrated the contribution of cross-talk
between EGFR and insulin-like growth factor 1 receptor (IGF-1R) to acquired resistance
against EGFR-targeted therapies [34–38]. These two receptors interact on multiple levels, ei-
ther indirectly via common interaction partners, or through a direct association (heterodimer)
at the cell surface [34, 39]. A number of clinical studies have shown that treatment of NSCLC
cells with EGFR TKIs can induce increased EGFR/IGF-1R heterodimerization and IGF-1R ac-
tivation [9, 34], enhancing the downstream PI3K/Akt and Mek/Erk pathways [9]. The prolifer-
ation of Erlotinib-resistant NSCLC cells (H460/TKI-R) were inhibited when treated with
AG1024 (IGF-1R-target), compared with those treated with continuous Erlotinib (EGFR-tar-
geted) (Fig 1g) [9]. It reveals the important role of IGF-1R in recovering signaling pathways
during NSCLC progression. More notably, strategies that dually target EGFR and IGF-1R
showed better antitumor efficacy than those targeting individual receptors in cancer therapies
[40–43]. Accordingly, IGF-1R was investigated as a heterodimerization partner of EGFR in
our study.
Amplification of c-Met (MET) [39, 44, 45] has been detected in lung cancer cells developing
resistance to Gefitinib or Erlotinib. This c-Met amplification leads to aberrant signaling that is
implicated in cell proliferation and migration [46, 47]. Progression of tumors with c-Met am-
plification are highly dependent on c-Met signaling, mediated by the heterodimers of c-Met
with EGFR, ErbB-2 and ErbB-3 [47]. These associations can be markedly reduced by treatment
with a c-Met kinase inhibitor or c-Met/ErbB dual inhibitors [47, 48]. As reported in [47], ef-
fects of depletion of c-Met, EGFR, ErbB-2 and ErbB-3 on cell proliferation (Fig 1h), of two
NSCLC cell lines (EBC-1 and H1993), showed the significant role that c-Met plays in NSCLC
progression. Specifically, c-Met can cause drug resistance by the association with ErbB-3 and
the posterior activation of PI3K/Akt signaling [46, 47]. In our study, the interactions between
c-Met and EGFR/ErbB-3 (especially for ErbB-3) are carefully examined and discussed.
Computational approaches have recently become an efficient and popular alternative for in-
vestigating drug resistance mechanisms and innovative drugs [49–52]. In these computational
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approaches, structure-based methods play an important role [15]. Previously, depending on
structure-based approaches, we constructed a personalized drug resistance prediction model
for a group of NSCLC patients [15]. These patients all have EGFR kinase mutations, which can
be roughly described by the binding affinities between the corresponding EGFR mutants and
the TKIs used in the treatments. By combining these simplified EGFR mutation features and
the personal features of these patients, an efficient personalized prediction model was con-
structed, with each patient treated as an input and his/her response level to a specific TKI as an
output. However, the characterization of each EGFR mutation may not be sufficient or com-
plete, as the mutation-driven modifications of EGFR-downstream or intracellular signaling
pathways are also important. A detailed description of each mutation type can lead to a gener-
alized model for the mapping from a mutation type to a specific TKI resistance level. The pro-
gression-free survival (PFS) of an inhibitor, recorded in unit of months or years, is a reliable
indicator of the drug resistance level [53]. In brief, screening for diverse EGFR mutation types
in lung cancers may identify patients that will response well to different TKIs. In this study we
analyzed the interactions between EGFR mutants and their potential dimerization partners
(e.g. ErbB-2, IGF-1R and c-Met) coupled with those between ErbB-3 and its partners (e.g.
EGFR mutants, ErbB-2, IGF-1R and c-Met). Our study relied on structural templates in the
protein data bank (PDB) [54], and adopted the molecular dynamics (MD) simulations as a
major analysis technique [55]. Using the enriched EGFR mutation features, exacted from both
the interactions with an inhibitor and with a partner, we established a generalized regression
model to predict the PFS of an inhibitor to a specific mutant. Besides, we explored the contri-
butions of different factors to the drug resistance level, in these NSCLC treatments. At last,
ErbB-3-partner interactions were comparably discussed, to provide a clear outline of ErbB-3
signaling in cancer development.
Materials and Methods
Approved by the Institutional Review Board of the University of Hong Kong/Hospital Authori-
ty Hong Kong West Cluster (HKU/HA HKW IRB), our clinical data were collected from the
Queen Mary Hospital. These data were analyzed anonymously, and all the patients involved in
the original data collection are no longer alive. Based on these patient data, a series of computa-
tional and statistical approaches were implemented for the analysis of drug resistance in
NSCLC treatments.
Data Collection
Specifically, this data set consists of 168 NSCLC patients (stages IIIB and IV) with mutations
on exons 18 to 21 of the EGFR tyrosine kinase domain [15]. Before TKI therapies, formalin-
fixed paraffin-embedded (FFPE) tumor biopsy samples of these patients were retrieved for
EGFR mutation analysis [53, 56]. Overall, they share a total of 37 EGFR mutation types (Tables
A to F in S1 File), including residue substitutions, deletions, insertions and double-point muta-
tions. These EGFR mutation types were revealed by direct sequencing [53]. Two TKIs, gefitinib
and erlotinib, were the main inhibitors used in the treatments of these patients. We carried out
clinical observations on these patients, with the PFSs of their corresponding inhibitors re-
corded (in unit of months).
MD Simulations
Initially, we determined the 3D structure of each EGFR kinase mutant based on homology
modeling, using scap [57] and loopy [58]. scap is a program for side-chain prediction and resi-
due mutation. It provides a series of side-chain rotamer libraries [59] for side-chain packing.
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Based on a structural template, scap predicts protein residues according to rotamer selection,
steric feasibility and energy preference [57, 60]. Mutations such as point mutations were han-
dled by scap in our study. In this modeling, the AMBER force field was selected in accordance
with following AMBER simulations, and the large side-chain rotamer library was used for a
thorough structural search. Similarly, loopy predicts loops and mutated sequences for protein
chains. Multiple initial conformations of the predicted/mutated sites are modeled using ab-ini-
tiomethods [58, 60], and each conformation is then closed by a random tweak method [61].
Side-chain assessment [57], steric feasibility and energy preference (colony energy) [58] are
combined to make the best prediction. Specifically, deletion- and insertion-mutations were
modeled by loopy, and the AMBER force field was applied as well. For each sampled structure
we executed a rough 5000-step AMBER minimization [55] for structural refinement. The
quantum mechanics/molecular mechanics (QM/MM) mechanism was implemented in this re-
finement, with the mutated neighborhood regarded as a QM region and the rest as a
MM region.
Once we obtained the refined structures of these mutants, we implemented two groups of
experiments using the AMBER software suite [55]. Specifically, the experiments focused on an-
alyzing the protein-ligand interactions and protein-protein interactions that concern our mod-
eled mutants. The AMBER software suite was designed for biomolecular simulations and
analysis, normally with a force field specified. Eq 1 shows a simple additive force field, adopted
by AMBER.
VðrÞ ¼ Ebonded þ Enonbonded
¼
X
bonds
Kbðb b0Þ2 þ
X
angles
Kyðy y0Þ2
þ
X
dihedrals
ðVn=2Þð1þ cos½n dÞ
þ
X
nonbij
ðAij=r12ij Þ  ðBij=r6ijÞ þ ðqiqj=rijÞ
ð1Þ
In our implementations, the ff99SB force ﬁeld was selected for proteins, due to its careful man-
agement of the helical and extended regions of protein backbones. Small ligands were handled
by the gaff force ﬁeld. Prior to any simulations, a solvent environment should be generated. A
truncated octahedron water box, based on the common TIP3P water model, was created for
each solute with a 10-angstrom (A

) buffer in each direction. The 10-A

buffer was selected to
compensate the large computational costs.
At the early stage, we studied the mutant-inhibitor systems [15]. Each mutant structure was
aligned to complex 2ITY [19] or 1M17 [62], assisted by the UCSF chimera [63], to construct
the mutant-gefitinib or mutant-erlotinib system. Consecutively, we executed a minimization, a
heating, a density equilibration, a constant pressure equilibration and a production MD simu-
lation, in the aforementioned solvent environment. On our computer sever with 12 3.47-GHz
processors, the series of operations approximately took 18 hours. We also tested the simula-
tions on a High Performance Computer Cluster (HPCC) [64], composed of a master node and
44 computer nodes with each having 16 cores. A 5-node computation for each system can re-
duce the computational time to less than 3 hours.
On the other hand, we investigated the mutant-partner systems. The asymmetric dimer
structure proposed in [20] was regarded as our dimer template. A potential dimerization part-
ner of EGFR, namely ErbB-2 or IGF-1R, was aligned to the position in the template where its
N-lobe face participates in the interactions with the C-lobe face of an EGFR mutant. c-Met has
a larger structural difference from ErbB-2 or IGF-1R in the N-lobe face, and the dimer template
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may not be suitable for it to provide the N-lobe face, therefore we align it to the position where
its C-lobe face interacts with EGFR, as a supplementary study. ErbB-3 has an impaired kinase
domain and acts as an ideal co-receptor, thus in our study it provides the C-lobe face in the
communications with its potential partners. Posterior to the computational solvation of each
acquired dimer complex, the dynamics of the system were simulated.
The entire system should be equilibrated prior to the crucial MD simulation. We employed
a similar series of equilibrating operations as for the mutant-inhibitor systems, including
• a short 1000-step minimization (the first half with the steepest descent steps) with weak posi-
tion restraints (weight of 2.0) on the dimer to remove bad contacts,
• a following 1000-step minimization (the first half with the steepest descent steps) on the
whole system without restraints,
• a 25-ps heating from 100 to 300 Kelvin (K) with week restraints on the dimer,
• a 25-ps density equilibration with weak restraints on the dimer,
• a 250-ps constant pressure equilibration at 300 K.
Owing to the higher complexity of a protein-protein system, compared to a protein-ligand sys-
tem, we implemented two minimizations on the system with and without restraints on the
dimer. Besides, the SHAKE setting and the temperature control were the same as those in [15],
and the time step was confined to 1 femtosecond (fs) to adjust the settings. The equilibration of
each system was verified through its temperature, density, energy and the backbone RMSD
curve of the dimer complex.
Consecutively, we generated the production MD simulation at an interval of 2 fs for 2 ns,
where we collected trajectory frames at a step of 10 ps and 200 frames in each trajectory. Im-
portantly, the stabilization of each system was confirmed by the backbone RMSD curve of its
mutant-partner complex, to guarantee a reliable calculation of the binding free energy.
Through applying the previously-mentioned 5-node computer cluster, the total computational
cost for each system can be reduced to less than 9 hours.
Binding Free Energy Calculation Based on the MM/GBSAmodel
The production MD simulations produced the motion trajectories of each solvated system, and
the binding free energy of the involved mutant-partner complex was calculated based on these
trajectories. Binding free energy is a reliable estimate of the binding affinity of a solvated recep-
tor-ligand system (protein-ligand or protein-protein). The fundamental theory is the thermo-
dynamic cycle, characterized by the following equation.
DGBind;Solv ¼ DGBind;Vacuum þ DDGSolv ð2Þ
Here ΔGBind,Solv or ΔGBind,Vacuum represents the free energy difference between the bound and
unbound states of a complex, in a solvent or vacuum environment. ΔΔGSolv is the difference be-
tween the solvation free energy of the complex and that of the two binding partners (Eq 3).
DDGSolv ¼ DGSolv;Complex  DGSolv;Receptor  DGSolv;Ligand ð3Þ
The Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculations per-
formed by AMBER [55] can efficiently estimate these free energy differences. ΔGBind,Vacuum is
approximated by the averaged interaction energy between the two binding units, with the en-
tropy component considered. The solvation free energy ΔGSolv is typically decomposed into the
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electrostatic and non-electrostatic components in the following equation,
DGSolv ¼ DGel þ DGnonel ð4Þ
Two types of interactions contribute to ΔGnonel, namely the favorable Van der Waals attraction
between the solute and the water molecules, and the unfavorable cost of breaking the structure
of the water around the solute. ΔGel is estimated as follows,
DGel ¼ 
1
2
X
ij
qiqj
fGBðrij;Ri;RjÞ
1 exp½KfGB
ε
 
ð5Þ
where q and R are the charge and radius respectively of an atom, r indicates the distance be-
tween two atoms, ε is the solvent dielectric, fGB and K are controllable parameters. The energy
form can be further simpliﬁed into Eq 6, with ρi standing for the van der Waals radius of an
atom.
DGel ¼ 
q2i
2ri
1 1
ε
 
ð6Þ
Specifically, the binding free energy ΔGBind,Solv is comprised of succeeding components, Van
der Waals forces (VDW), electrostatic interactions (EEL), and the polar (EGB) and non-polar
(ESURF) contributions of the solvation free energies. In order to provide an efficient computa-
tion, AMBER normally neglects the entropy contribution to these energies for similar systems.
For the WT protein and each EGFR mutant, we calculated their binding free energies with gefi-
tinib, erlotinib, ErbB-2, ErbB-3, IGF-1R and c-Met, respectively. The distributions of these en-
ergies and their components were comparably and specifically analyzed.
As discussed above, ErbB-3 is a kinase-impaired co-receptor, suggesting it may not be as a
favorable partner as ErbB-2, IGF-1R or c-Met, for TKI-blocked EGFRs. However, it can be a
potential partner for ErbB-2, IGF-1R or c-Met. In this regard, we considered the EGFR-partner
interactions and the ErbB-3-partner interactions separately, leaving the ErbB-3-related study
as a supplementary one. First, we explored the dependence between the EGFR-partner/EGFR-
inhibitor interaction patterns and the PFSs of our NSCLC patients, after which we compared
and discussed different ErbB-3-partner interactions.
Regression to the PFS Based on Binding Free Energy Components of
EGFRMutant-partner/mutant-inhibitor Systems
For each patient, the PFS of the inhibitor used in his or her therapy was recorded. All these pa-
tients were grouped according to their EGFR mutation types and the involved inhibitors (gefiti-
nib and erlotinib). Each pair of a mutation type and an inhibitor corresponds to a PFS, which is
the median or average of the PFSs regarding the group of patients harboring this mutation and
treated with this inhibitor. When calculating the average, both the largest and lowest values
were discarded to reduce possible bias. Now we focus on a generalized investigation on the re-
sistance level of a specific mutation type to an inhibitor, for the scenario where patient data are
deficient. This differs from the personalized study concerning each patient [15].
Posterior to an outlier-removal operation on these PFS values, we simply adopted the re-
gression trees [65] for mapping the aforementioned energies or energy components to these
PFS values. The classification and regression trees (CART) are a simple but efficient method
for handling classification and progression problems. Given a set of samples, the mechanism
starts at a single node, and partitions the node in a binary way when the largest impurity reduc-
tion is achieved. The partitioning continues until the error reaches a stopping criterion.
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Common impurity measures include entropy (Eq 7) and Gini-index (Eq 8),
EðXÞ ¼ 
X
x2X
pðxÞlog pðxÞ ð7Þ
GðXÞ ¼ 1
X
x2X
pðxÞ2 ð8Þ
where x indicates a possible value of the variable X, and p(x) represents the frequency of x in a
discrete case.
Two common indexes, the relative absolute error (RAE) and root relative square error
(RRSE), were selected to evaluate the regression performances in our implementations. These
two measures can be formulated as Eqs 9 and 10,
RAE ¼
Xn
i¼1
jPi  Tij
Xn
i¼1
jTi 
1
n
Xn
i¼1
Tij
ð9Þ
RRSE ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXn
i¼1
ðPi  TiÞ2
Xn
i¼1
Ti 
1
n
Xn
i¼1
Ti
 !2
vuuuuuuut ð10Þ
where Pi and Ti represent the predicted and target values of the ith sample, respectively. Nor-
mally, the RAE or RRSE values fall into the range of [0, 1], and a favorable performance corre-
sponds to a value approximating to zero. Based on different sets of energy features, including
the total binding free energies or energy components of the EGFR mutant-inhibitor/mutant-
partner systems, we performed the regression analysis and evaluated the results using the RAE
and RRSE values.
Investigation of ErbB-3-partner Interactions
Ultimately, interactions between ErbB-3 and its partners, characterized similarly using binding
free energy and its components, were analyzed. All the patient-derived EGFR mutants coupled
with c-Met, ErbB-2 and IGF-1R, were considered in our analysis as an ErbB-3 partner. The in-
teraction patterns of these ErbB-3-partner systems were comparably examined, especially for
those involving well-know EGFR mutants (L858R, L858R_T790M) and c-Met.
Results and Discussion
Three-dimensional Templates
Two inhibitors, gefitinib and erlotinib, are broadly applied in the NSCLC treatments [66, 67].
Specifically for our 168 patients with stages IIIB and IV NSCLC, 137 of them were treated with
gefitinib and the rest (31 cases) with erlotinib [15, 53]. The 3D structures of these two inhibi-
tors, respectively separated from complexes 2ITY [19] and 1M17 [62] in the PDB [54], are ex-
hibited in Fig 2b and 2d respectively, and these structures were utilized as ligand templates in
our major MD simulations. Component atoms of gefitinib and erlotinib are shown in Fig 2a
and 2c, with their essential pharmacophore (quinazoline ring) highlighted in a red box.
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Besides, the patients possess 37 types of EGFR mutations (Tables A to F in S1 File), which
correspond to mutations in exons 18 to 21 of the EGFR tyrosine kinase domain. To gain a
deeper insight into these mutations, we firstly decoded their 3D structures based on the corre-
sponding protein sequences and a 3D template, and these predicted mutants were used in our
succeeding MD simulations. TwoWT EGFR kinase proteins (active form) in complexes 2ITY
and 2ITZ [19] were regarded as our templates for the mutant prediction. Complex 2ITY is dis-
played in Fig 2e, where the N-lobe, C-lobe, and primary drug-interacting residues of the kinase
domain are shown. Majority of mutants were modeled based on 2ITY, which contains the wild
type (WT) EGFR kinase. Those L858R-related mutants, such as L858R_T790M, were handled
using 2ITZ that involves the kinase domain of mutant L858R. Both 2ITY and 2ITZ were re-
solved in [19], and thus they share similar structural details and can be comparably used as our
Fig 2. The three-dimensional templates in our structural analysis. (a) and (b), The structures of gefitinib (PDB: 2ITY), with its atoms and essential
pharmacophore (quinazoline ring) shown. (c) and (d), The structures of erlotinib (PDB: 1M17), with its atoms and essential pharmacophore (quinazoline ring)
shown. (e) Complex 2ITY (in PDB), composed of an active WT EGFR kinase (N-lobe + C-lobe) and an inhibitor (gefitinib); major gefitinib-interacting residues
are labeled as red balls. (f) to (i), The structures of the kinase domains of ErbB-2 (PDB: 3PP0), ErbB-3 (PDB: 4RIW), IGF-1R (PDB: 1K3A) and c-Met (PDB:
1R1W), respectively. (j) The asymmetric dimer that is formed by twoWT EGFR kinases.
doi:10.1371/journal.pone.0128360.g002
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templates. At the early stage, we examined the binding affinity of each mutant-inhibitor system
[15], which was an important index for studying the potency of an inhibitor (or drug resistance
level) to a specific EGFR kinase mutant. Complex 2ITY was adopted as a mutant-inhibitor
template for a rough formation of the system, prior to the AMBER minimizations
or simulations.
The regulation of the EGFR downstream signaling pathways is vital for the efficacy of an in-
hibitor or the occurrence of drug resistance, thus analyzing the EGFR-partner interactions in
these pathways can provide valuable clues to our study. The homo- or hetero-dimerization of
EGFR with its partners is the origin of these signaling pathways, and it is quite an important
factor for the downstream signaling regulation. Based on our early study on the mutant-inhibi-
tor systems, we extended our investigation to that on the mutant-partner systems. Potential di-
merization partners of EGFR, namely ErbB-2 (PDB: 3PP0) [68], IGF-1R (PDB: 1K3A) [69]
and c-Met (PDB: 1R1W) [70], were analyzed in our work. Since ErbB-3 (PDB: 4RIW) [28] is
an efficient co-receptor, ErbB-3-partner interactions were considered as well. The 3D struc-
tures of these proteins are shown in Fig 2f–2i. At last, the asymmetric dimer (Fig 2j) [20] was
employed as a dimer template for EGFR mutant-partner and ErbB-3-partner systems, to pro-
vide a rough input to the primary MD simulations. For simplicity, we will abbreviate ‘EGFR
mutant’ to ‘mutant’ in the following sections.
System Construction and MD Simulation Results
As described previously, the 3D structures of the 37 EGFR mutants were translated from the
protein sequences based on a template. Scap [57] and loopy [58] handled the structure predic-
tion. Specifically, scap deals with side chain substitutions (point mutations), which are notated
by the abbreviations of the amino acid residues at the mutated positions, such as L858R. In ad-
dition, loopymanages residue deletions and insertions, which respectively are notated by pre-
fixes ‘del’ and ‘ins’, such as delE746_A750 and delL747_A755insSKG. Also, duplications of
residue, regarded as a sort of residue insertion, are notated using prefix ‘dul’ such as dulH773.
Besides, a double-point mutation is named by a connection of two single-point mutations,
such as L858R_T790M. Some detailed modeling results can be found in our early studies [15].
Since the mutations normally occur at the TKI-binding site or its neighborhood of EGFR tyro-
sine kinase domain, we further conducted a structural investigation on the TKI-binding caves
of our mutants. Fig 3 shows several instances, including WT EGFR (Fig 3a), L858R (Fig 3b and
3g), L858R_T790M (Fig 3c), delE746_A750 (Fig 3h) and delL747_P753insS (Fig 3i). For sim-
plicity, we merely observed the gatekeeper position (790), which was regarded as an important
sign for drug efficacy or resistance in early studies [22]. Fig 3a–3c present a comparison among
the WT EGFR, mutant L858R, and mutant L858R_T790M. L858R is a well-know good re-
sponder to TKIs, and its flat gatekeeper position shows a larger affinity with Gefitinib (Fig 3b).
WT EGFR (Fig 3a) and L858R_T790M (Fig 3c) contain a more concave or convex gatekeeper
position, which may resist the binding with TKIs. To further clarify the structural difference,
we present the major binding-site residues in Fig 3d–3f, with the gatekeeper residues labeled.
Moreover, the comparison among L858R, delE746_A750, and delL747_P753insS are shown in
Fig 3g–3l. This implies, compared to delL747_P753insS, L858R or delE746_A750 may have a
better affinity with TKIs.
Before the major MD simulations, each mutant structure was roughly minimized for 5000
AMBER steps. In our major AMBER simulations, we implemented two groups of experiments.
One focused on the mutant-inhibitor systems that each involves an EGFR mutant and an in-
hibitor (gefitinib or erlotinib), and the other concerned with the mutant-partner (or ErbB-
3-partner) systems with each comprising a mutant and a dimerization partner (ErbB-2, IGF-
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1R or c-Met). For the first group, each mutant structure was aligned to the template complexes
to form its mutant-inhibitor complexes. In the AMBER minimizations or simulations, the gen-
eralized AMBER force field (gaff) and the AM1-BCC charge method [71] were employed to
handle the inhibitors, prior to the computational solvation of each system into a water environ-
ment. After a series of equilibrating operations, consisting of a short minimization (1000
steps), a heating phase (50 picoseconds (ps)), a density equilibration (50 ps) and a constant
pressure equilibration (500 ps), we carried out the crucial MD simulation for 2 nanoseconds
(ns). The stabilization of each system was verified by the backbone root-mean-square deviation
(RMSD) curve of the corresponding mutant in the production MD simulation phase (2 ns)
[15].
Aside from the analysis on the mutant-inhibitor systems, we carried out a series of simula-
tions on the newly-constructed mutant-partner or ErbB-3-partner systems. After computa-
tionally solvating each system into a water environment, we equilibrated the system at first,
similar to the aforementioned operations for the mutant-inhibitor systems. These equilibrating
steps encompass two short minimizations with and without restraints (each for 1000steps), a
heating phase (25 ps), a density equilibration (25 ps) and a constant pressure equilibration
(250 ps). Afterwards, a production MD simulation of 2 ns was implemented. The stabilizations
of these systems were verified as well, and Fig 4 shows the RMSD curves of several important
EGFR mutant-partner complexes, indicating acceptable stabilizations of their
corresponding systems.
Characterization of Molecular Binding Affinity
Based on the production MD simulation trajectories, we characterized the binding affinity of a
solvated mutant-inhibitor or mutant-partner/ErbB-3-partner system. Binding free energy is a
favorable estimate of this binding affinity, which can be derived by performing Molecular Me-
chanics / Generalized Born Surface Area (MM/GBSA) calculations [55] using AMBER. The
GB model efficiently computes different types of free energy differences, and further constructs
the binding free energy components of VDW, EEL, EGB and ESURF. We calculated the bind-
ing free energy and its components for each system (Tables A to F in S1 File), and regarded
those concerning the WT protein (WT—Gefitinib, WT—Erlotinib, WT—ErbB-2, WT—IGF-
1R andWT—c-Met systems) as baselines for normalization of mutant-inhibitor/mutant-part-
ner interactions. ErbB-3-partner interactions will be discussed separately afterwards.
The distributions of binding free energies and their components, for each EGFR mutant (or
WT protein) and an inhibitor or a dimerization partner, are presented in Fig 5a–5e. Further-
more, we comparably display the total binding free energies concerning the five kinds of sys-
tems in Fig 5f, with the mutation types listed. Also, the statistics of the 37 EGFR mutation types
among our 168 patients are presented in Fig 5g, where the three peaks are delE746_A750,
delL747_P753insS and L858R respectively. We can see that, type delL747_P753insS is some-
what distinct from the other two peaks whose energies concentrate more. In the following
Fig 3. Structural comparison of the TKI-binding caves of several EGFRWT or mutant proteins, with Gefitinib exhibited. (a) to (c), Structural
comparison among TKI-binding caves of WT EGFR, mutant L858R, and mutant L858R_T790M; major differences at the gatekeeper position (790) are
labeled with green circles. (d) to (f), Binding-site residues of WT EGFR, mutant L858R, and mutant L858R_T790M, with residues colored as follows, LEU
(red), ALA (green), GLY (blue), LYS (yellow), GLU (magenta), MET (cyan), THR (dark red), GLN (dark green), and PRO (dark blue). (g) to (i), Respective TKI-
binding caves of mutants L858R, delE746_A750 and delL747_P753inS, with major structural differences at the gatekeeper position labeled. (j) to (l), Colored
binding-site residues of mutants L858R, delE746_A750 and delL747_P753inS.
doi:10.1371/journal.pone.0128360.g003
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interpretations, we will analyze some specific mutants, including the well-known type
L858R_T790M, for a further discussion.
Now we analyze several specific instances by simply employing the total binding free energy.
A low energy value, corresponding to a high absolute value, indicates a high binding affinity.
Above all, we investigated the WT protein, mutant L858R (frequently occurs in NSCLC and re-
sponses well to TKIs) and mutant L858R_T790M (a double-point mutation that commonly
triggers drug resistance). Fig 6a displays the binding free energies of these mutants with ErbB-
2, IGF-1R, c-Met, gefitinib and erlotinib, respectively. Regarding the inhibitors, L858R binds
more tightly with gefitinib than with the WT protein, while L858R_T790M binds less tightly
with either gefitinib or erlotinib than with L858R. In addition, the binding of these mutants
with ErbB-2 or IGF-1R gradually becomes tighter following the sequence of (i) the WT protein,
(ii) L858R, and (iii) L858R_T790M. Regarding c-Met, L858R_T790M binds more tightly with
Fig 4. Backbone RMSD curves of several EGFRmutant-partner systems in the 2-ns production MD simulations. (a) to (c), The RMSD curves for the
WT—ErbB-2, WT—IGF-1R andWT—c-Met systems, respectively. (d) to (f), The curves for the mutant L858R-related systems. (g) to (i), The scenarios
where the mutant delE746_A750 is involved. (j) to (l), The curves for the systems concerning mutant delL747_P753insS.
doi:10.1371/journal.pone.0128360.g004
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it than with the WT protein or L858R. A tighter binding of the dimerization partners implies a
stronger recovery of the downstream signaling pathways, thus brings negative effects to the ef-
ficacy of an inhibitor. The attenuated binding between mutant L858R_T790M and a TKI com-
pared with that between L8585 and a TKI was well-verified in previous studies [19, 22, 23],
sustaining our above analysis. As reported in [9, 34], strengthened EGFR-IGF-1R heterodimer-
ization was found in NSCLC TKI-resistant cells than non-resistant cells, which is consistent to
our results regarding mutants L858R (non-resistant) and L858R_T790M (TKI-resistant). Also,
the increased EGFR-c-Met interaction in TKI-resistant cells (L858R_T790M) can be supported
by the work in [47]. Combining these findings, we can explain the favorable efficacy of the in-
hibitors to L858R, and the resistance to L858R_T790M. Importantly, the mutant-partner
Fig 5. Binding free energy and its components of eachmutant-inhibitor or mutant-partner system. (a) to (c), The energies for the systems that each
involves a mutant and a dimerization partner (ErbB-2, IGF-1R or c-Met). (d) and (e), The energies for those systems concerning a mutant and an inhibitor
(gefitinib or erlotinib). (f) The total binding free energies extracted from parts a to e, with the mutation types shown. (g) The statistical results of the mutation
types among our NSCLC patients.
doi:10.1371/journal.pone.0128360.g005
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interactions may be indispensable to the efficacy of an inhibitor or can cause the occurrence of
drug resistance.
Subsequently, we sorted the total binding free energies concerning all the mutation types of
our patients in Fig 6b–6f, with the mutation types listed. As an example, L858R has a largest
binding free energy with gefitinib, a low binding free energy with ErbB-2 (fifth from the last),
and an average binding affinity with either IGF-1R, c-Met or erlotinib.
Since the mutant-partner interactions can bring a negative influence to the efficacy of an in-
hibitor while the mutant-inhibitor interactions produce a positive one, we further extract the
total binding free energy difference between them for a detailed analysis. Fig 7a shows the
Fig 6. Total binding free energies of the mutant-inhibitor or mutant-partner systems, involving several specific mutants. (a), The total binding free
energies between several important EGFR kinases (WT, L858R, L858R_T890M) and a dimerization partner (ErbB-2, IGF-1R, c-Met) or an inhibitor (gefitinib,
erlotinib). (b) to (f), Ranked binding free energies for the systems regarding all of our mutants (37 types + WT + L858R_T790M) in an ascending order.
doi:10.1371/journal.pone.0128360.g006
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energy difference of the mutant-gefitinib and the mutant-ErbB-2 systems for each mutant,
with the differences ranked in a descending order. Similarly, Fig 7b displays the energy differ-
ence between the mutant-erlotinib and mutant-ErbB-2 systems for each mutant. Each total
binding free energy value has a negative sign; therefore, a larger difference value indicates a
lower efficacy of the inhibitor or a higher drug resistance level. Likewise, Fig 7c–7f reveal how
the energy differences, concerning IGF-1R/c-Met and the two inhibitors, distribute.
Fig 7 uncovers that, L858R corresponds to a largely-negative value in either part a, b, or e, and
an averaged-positive value in part c, d, or f. Besides, in all these six scenarios, L858R_T790M
ranks higher than L858R, implying a higher drug resistance level. delL747_P753 is a frequent-
Fig 7. The difference between the total binding free energies of the mutant-inhibitor system and the mutant-partner system for eachmutant. (a)
and (b), The binding free energy differences between the systems involving ErbB-2 and the two inhibitors (gefitinib and erlotinib), with the values ranked in
the descending order. (c) and (d), The similar binding free energy differences between the systems concerning IGF-1R and the two inhibitors. (e) and (f), The
binding free energy differences between the systems concerning c-Met and the two inhibitors.
doi:10.1371/journal.pone.0128360.g007
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occurred mutation associated with deletions in exon 19 [72, 73], and it was commonly reported
to have poor or even worst clinical outcomes among NSCLC patients [16, 53, 73]. As shwon in
[53], delL747_P753insS has the shortest PFS among all the examined mutations, indicating a
high drug resistance level. Furthermore, in [16], the mutation was concluded to trigger increased
growth factor signaling and confer susceptibility to inhibitors. Strikingly, delL747_P753insS com-
monly occurs among our patients, and ranks the first in Fig 7c and 7d, possessing a larger differ-
ence than other mutations. Also, it ranks higher in either part e or f. It implies that, IGF-1R or c-
Met may be a crucial factor that influences the EGFR signaling and promotes the drug resistance
level in NSCLC treatments. In the subsequent section, we will bring the energy components into
the discussion, to broaden our investigation.
Regression Results from Binding Free Energy Components to PFS
In order to explore the effects of an inhibitor to a specific mutation type, we categorized our pa-
tients into groups where patients in each group share the same mutation type and inhibitor.
Each group corresponds to a PFS extracted from the PFSs of the component patients, either as
a median or an evolved average (the largest and lowest values were excluded). The medians
scatter in Fig 8a, where the red circle is an apparent outlier and was discarded in our studies.
We regarded the previously-obtained energies as features for each group, and aimed to con-
struct a mapping from the energy to the PFS. The regression trees [65], was applied in the
study. To ease our succeeding illustrations, we notate the binding free energies or their compo-
nents in different scenarios as follows,
• MI1,MI2,MI3 andMI4 represent the four components (VDW, EEL, EGB and ESURF) of the
binding free energy between the mutant and inhibitor concerning each patient group, and
MI indicates the total binding free energy.
• ME1,ME2,ME3 andME4 are the components of the binding free energy between a mutant
and its partner ErbB-2, and ME is the total binding free energy.
• MG1,MG2,MG3 andMG4 stand for the components of the binding free energy regarding a
mutant and its partner IGF-1R, and MG is the total binding free energy.
• MC1,MC2,MC3 andMC4 stand for the components of the binding free energy regarding a
mutant and its partner c-Met, and MC is the total binding free energy.
To compare the influences of different factors to the PFS of an inhibitor, which implies the re-
sistance level to this inhibitor, we constructed feature sets S1 to S9 as defined below,
• S1 = (MI1,MI2,MI3,MI4),
• S2 = (MI1,MI2,MI3,MI4,ME1,ME2,ME3,ME4),
• S3 = (MI1,MI2,MI3,MI4,MG1,MG2,MG3,MG4),
• S4 = (MI1,MI2,MI3,MI4,MC1,MC2,MC3,MC4),
• S5 = (MI1,MI2,MI3,MI4,ME1,ME2,ME3,ME4,MG1,MG2,MG3,MG4),
• S6 = (MI1,MI2,MI3,MI4,ME1,ME2,ME3,ME4,MC1,MC2,MC3,MC4),
• S7 = (MI1,MI2,MI3,MI4,MC1,MC2,MC3,MC4,MG1,MG2,MG3,MG4),
• S8 = (MI1,MI2,MI3,MI4,ME1,ME2,ME3,ME4,MG1,MG2,MG3,MG4,MC1,MC2,MC3,
MC4),
• S9 = (MI,ME,MG,MC).
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A regression analysis was conducted on each feature set, with the results exhibited in Fig 8b–8j.
Besides, the relative absolute errors (RAEs) and root relative square errors (RRSEs), generally
used for evaluating the regression performances, are listed in Table 1 for these scenarios in
both cases involving the median PFSs and average PFSs. As revealed in Fig 8, the interaction in
a mutant-inhibitor system (feature set S1) is a fundamental element for predicting the drug re-
sistance level concerning gefitinib or erlotinib. Bringing in the interaction in a mutant-ErbB-2
or mutant-c-Met system (feature set S2 or S4) leads to a higher RAE (0.4796, 0.4854 / 0.5694,
0.5439) or RRSE (0.5742, 0.5694 / 0.6946, 0.6937) in both scenarios. It may reveal that, ErbB-2
is not a significant factor in controlling the drug resistance in NSCLC treatments, while it has
been broadly acknowledged to be important in the treatments of breast cancer [33, 74]. c-Met
was well-verified to be an important co-factor for ErbB-3 to activate ErbB-3 signaling, in lung
Fig 8. A regression analysis on different feature sets and the median PFS values for patient groups. (a) The median PFS values (in months) for all the
patient groups, with an outlier circled. Each blue point represents a patient group, where the included patients share the same EGFRmutation type and
inhibitor. (b) to (j), The regression results based on features sets S1 to S9, after an outlier-removal from part a. The blue curves indicate the predicted PFS
values for our patient groups.
doi:10.1371/journal.pone.0128360.g008
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cancer cells developing resistance to TKIs [46, 47]. Therefore, in this scenario, the major role of
c-Met in communicating with ErbB family receptors may be decoded by c-Met-ErbB-3 interac-
tions. These will be discussed in the following section. It is noteworthy that, the adoption of the
interaction in a mutant-IGF-1R system (feature set S3) can improve the regression perfor-
mances with a lower RAE (0.3168 / 0.3239) or RRSE (0.3437 / 0.3433), in both situations. IGF-
1R may behave as a vital role in regulating the EGFR signaling pathways, therefore influences
the resistance level to an inhibitor in NSCLC treatment. Feature set S9 corresponds to the worst
performance, indicating the concealed information in the components of binding free energies.
Ultimately, an example regression tree based on feature set S3 is presented in Fig 9. As
shown in this figure, components VDW (MG1) and EGB (MG3) of the binding free energies, in
mutant-inhibitor systems, participate in the tree construction. Especially,MG3 occurs three
times, implying this component may be an important factor to influence TKI efficacy in
NSCLC treatments. Moreover, components VDW (MI1), EGB (MI3), and ESURF (MI4) of the
binding free energies, in mutant—IGF-1R systems, primarily contribute to the tree construc-
tion. The VDW component is adopted twice for this prediction, indicating it may be useful in
the drug resistance prediction in lung cancer studies. This tree model can be further improved,
when involving more accurate structural analysis and sufficient patient data in future studies.
Investigation of ErbB-3-partner Interactions Based on Binding Free
Energies
Binding free energies of ErbB-3-partner systems, involving ErbB-3 and its partners EGFR mu-
tants, c-Met, ErbB-3 and IGF-1R, were similarly derived as those of mutant-partner systems.
The stabilizations of these systems, in the 2-ns production MD simulation, were validated and
the RMSD curves of several instances are shown in Fig 10a–10f. Binding free energies and their
components for the examined systems are shown in Fig 10g. In addition, the results involving
EGFR mutants were averaged, and compared to ErbB-3—c-Met, ErbB-3—ErbB-2 and ErbB-3
—IGF-1R systems (Fig 10h).
Table 1. RAE and RRSE values for the regressions.
Median PFS
Set S1 S2 S3 S4 S5 S6 S7 S8 S9
Measure
RAE 0.3434 0.4796 0.3168 0.5694 0.3168 0.5206 0.5346 0.5061 0.6980
RRSE 0.5125 0.5742 0.3437 0.6946 0.3437 0.6836 0.6893 0.6824 0.7760
Evolved Average PFS
Set S1 S2 S3 S4 S5 S6 S7 S8 S9
Measure
RAE 0.4021 0.4854 0.3239 0.5439 0.3239 0.4996 0.5288 0.4775 0.8091
RRSE 0.5299 0.5694 0.3433 0.6937 0.3433 0.6832 0.6935 0.6802 0.8160
Different feature sets S1 to S9 were tested in the regression analysis, with the median PFS or evolved average PFS applied. S1 indicates the mutant-
inhibitor interaction; S2 further brings in the mutant-ErbB-2 interaction; S3 focuses on both the mutant-IGF-1R and mutant-inhibitor interactions; and S4
includes both the mutant-c-Met and mutant-inhibitor interactions. S5 to S7 each includes the mutant-inhibitor interaction and two kinds of mutant-partner
interactions, and S8 or S9 considers all the four kinds of interactions. Speciﬁcally, S1 to S8 apply the binding free energy components, while S9 only adopts
the total binding free energy.
doi:10.1371/journal.pone.0128360.t001
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Further, we investigated the total binding free energies of ErbB-3-partner systems (Fig 10i),
and ranked several representatives (Fig 10j). In Fig 10i and 10j, both ErbB-2 and IGF-1R bind
less tighter with ErbB-3 than majority of EGFR proteins, while c-Met presents a significantly-
strong binding with ErbB-3 compared to these EGFR mutants. This may imply the positive
contribution of c-Met in promoting the ErbB-3 signaling in lung cancer cells [46, 47]. Besides,
mutants such as L858R, L858R_T790M, delE746_A750 and delL747_P753insS have a lower
binding affinity with ErbB-3 than the WT protein does, suggesting larger differences between
such interactions and the ErbB-3—c-Met interaction. As mutations L858R_T790M and
delL747_P753insS largely corresponded to poor clinical outcomes and active TKI resistance
[16, 22, 23, 53], their decreased binding with ErbB-3 may encourage the binding between c-
Met and ErbB-3, which strengthens the ErbB-3 downstream signaling. After considering the
energy differences between each ErbB-3-mutant system and the ErbB-3-c-Met system, the
Fig 9. A regression tree generated based on feature set S3. S3 = (MI1,MI2,MI3,MI4,MG1,MG2,MG3,MG4), which includes the interaction patterns,
characterized by binding free energy components, in a mutant-IGF-1R or mutant-inhibitor system for each patient group. Patients in the same group share
the same EGFRmutation type and inhibitor.
doi:10.1371/journal.pone.0128360.g009
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above-mentioned regression performances can be further improved to 0.3036/0.3359 and
0.2965/0.3338 for RAE/RRSE in the two secnarios (Median PFS and Evolved Average PFS).
Summary and Future Works
Computational biology has become an indispensable branch of life sciences [49–52]. The
computational and structural studies nourished many fields, such as the prediction of molecu-
lar structures or interactions [75], the construction of the protein function network [76], and
the discovery of innovative drugs [77]. In our work, 37 EGFR mutants, extracted from our 168
Fig 10. Computational results for ErbB-3-partner systems. (a) to (f), Respective backbone RMSD curves of ErbB-3—WT, ErbB-3—L858R, ErbB-3—
L858R_T790M, ErbB-3—c-Met, ErbB-3—ErbB-2 and ErbB-3—IGF-1R systems, in the 2-ns production MD simulations. (g) Binding free energies and their
components of ErbB-3-partner systems. (h) Binding free energies and their components of ErbB-3—EGFRmutant (averaged), ErbB-3—c-Met, ErbB-3—
ErbB-2 and ErbB-3—IGF-1R systems. (i) Total binding free energy comparison among ErbB-3-partner systems. Binding free energies of ErbB-3—c-Met,
ErbB-3—ErbB-2 and ErbB-3—IGF-1R systems are labeled with lines, and those of systems involvingWT EGFR, L858R, L858R_T790, delE746_A750 and
delL747_P753insS are marked with solid spheres. (j) Ranked total binding free energies of representative ErbB-3-partner systems.
doi:10.1371/journal.pone.0128360.g010
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NSCLC patients, were investigated based on their 3D structures. Both the mutant-inhibitor
and mutant-partner interactions were characterized using the binding free energy and its com-
ponents, based on the molecular dynamics of these systems. Specifically, mutant
L858R_T790M has a weaker connection with the inhibitors (gefitinib and erlotinib) but a
stronger interaction with the dimerization partners (ErbB-2, IGF-1R and c-Met), compared to
mutant L858R. Further, mutant delL747_P753insS corresponds to an apparently high differ-
ence between its interactions with IGF-1R and an inhibitor (gefitinib or erlotinib). These obser-
vations may support the significant contribution of IGF-1R to the resistance level concerning
an inhibitor. Moreover, the binding free energy components were brought in to construct a
generalized regression model for predicting the PFS of an inhibitor. Regression trees [65], in-
volving different energy feature sets, confirmed the positive influence of IGF-1R in regulating
the drug resistance level in NSCLC treatments. As a supplementary study, interactions between
ErbB-3 and its potential partners were analyzed and compared, similarly relying on the binding
free energies. c-Met corresponded to a stronger binding with ErbB-3 than EGFR mutants, sug-
gesting its important influence in strengthening ErbB-3 signaling.
The study or prediction of drug resistance level in a cancer therapy is vital for cancer-related
research. To explore the links (proteins or complexes) in cancer signaling networks can bring
promising results. In our work, the contribution of EGFR and ErbB-3 heterodimerization to
the drug resistance mechanism in NSCLC treatments was analyzed, according to a structural
perspective. The significant influences of IGF-1R and c-Met in the EGFR/ErbB-3 downstream
signaling were further verified. Dually-targeting inhibitors, such as those targeting both EGFR
and IGF-1R, may produce a good efficacy. These findings can encourage the development of
innovative drug discovery or specialized therapy design. In future studies, proteins relating to
different links in cancer signaling pathways can be our targets, based on which we will gain a
deeper insight into the drug resistance mechanism and further improve our prediction model.
As another part of our future goals, more efficient strategies should be explored to further de-
crease the computational costs of calculating the binding affinity of a protein-inhibitor or pro-
tein-protein system.
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